# GRIT Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/grit-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.grit-bio.com
- Total disclosed funding: $154M
- Latest round: Series C (Sep 30, 2025)
- Investors on record: 14

## About

Established in 2019 and based in Shanghai, China, GRIT Biotechnology is an innovative cell therapy company that engages in the development and application of tumor infiltration lymphocytes (TIL). It focuses on the Development of solid tumor immunotherapy. Some enterprises, such as Shanghai Junshi Biosciences Co., Ltd., Decheng Capital, Hillhouse, and Sherpa Healthcare Partners, have cooperated with the company. In September 2023, GRIT Biotechnology raised a CNY 400 million in series B funding.

The company mainly develops TIL therapies without genetic modification to treat malignant tumors. It has established three technology platforms to support the development of TIL therapies which are stable virus production cell lines, immunomodulatory target screening and Stemness TIL amplification technology. The company's products are currently undergoing clinical trials in China.

GRIT Biotechnology will focus on the development of the company's tumor-infiltrating lymphocyte (TIL) therapy pipeline, including the pivotal clinical trial of GT101 and the development of several next-generation gene-edited TIL pipelines.

## Funding rounds

- Series C, Sep 30, 2025, $84M — Loyal Valley Capital, Juntuo Bio
- Series B, Sep 8, 2023, $54M — China International Capital Corporation, Decheng Capital, MPC, Qianhai Ark Capital, Sherpa Healthcare Partners, Liandong Group, Yuanhe Fund, HeFangTian Venture Partnership
- Series A, Jul 16, 2021 — Decheng Capital, MPC, Apricot Capital, Shanghai Junshi Biosciences Co., Ltd., GL Ventures
- Series A, Dec 11, 2020, $15M — Decheng Capital, MPC, Sherpa Healthcare Partners
- Angel, Aug 24, 2020 — Hengqin Financial Investment

## Investors

- Hengqin Financial Investment (https://capitalatlas.ai/funds/hengqin-financial-investment) — Angel
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A, Series B
- MPC — Series A, Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A
- Shanghai Junshi Biosciences Co., Ltd. — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series B
- Liandong Group — Series B
- Yuanhe Fund — Series B
- HeFangTian Venture Partnership — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series C
- Juntuo Bio — Series C